Lionco Pharm Grp Co Ltd Asset Resilience Ratio
Lionco Pharm Grp Co Ltd asset resilience ratio. Lionco Pharm Grp Co Ltd (603669) has an Asset Resilience Ratio of 0.38% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603669 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lionco Pharm Grp Co Ltd (2015–2025)
Asset resilience ratio of Lionco Pharm Grp Co Ltd from 2015 to 2025. This chart shows how Lionco Pharm Grp Co Ltd's Asset Resilience Ratio has changed over time. Read Lionco Pharm Grp Co Ltd (603669) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lionco Pharm Grp Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lionco Pharm Grp Co Ltd (603669) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥4.31 Million | 0.38% |
| Total Liquid Assets | CN¥4.31 Million | 0.38% |
Asset Resilience Insights
- Limited Liquidity: Lionco Pharm Grp Co Ltd maintains only 0.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lionco Pharm Grp Co Ltd Industry Peers by Asset Resilience Ratio
Compare Lionco Pharm Grp Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.23% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.95% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728 |
Drug Manufacturers - Specialty & Generic | 9.66% |
Lionco Pharm Grp Co Ltd Asset Resilience Ratio by Year (2015–2025)
Lionco Pharm Grp Co Ltd asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Lionco Pharm Grp Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.20% | CN¥13.32 Million ≈ $1.95 Million |
CN¥1.11 Billion ≈ $161.96 Million |
-1.28pp |
| 2024-12-31 | 2.49% | CN¥31.22 Million ≈ $4.57 Million |
CN¥1.26 Billion ≈ $183.69 Million |
-21.56pp |
| 2023-12-31 | 24.04% | CN¥390.59 Million ≈ $57.16 Million |
CN¥1.62 Billion ≈ $237.72 Million |
+3.05pp |
| 2022-12-31 | 20.99% | CN¥389.51 Million ≈ $57.00 Million |
CN¥1.86 Billion ≈ $271.51 Million |
-2.04pp |
| 2021-12-31 | 23.03% | CN¥579.13 Million ≈ $84.74 Million |
CN¥2.51 Billion ≈ $367.93 Million |
+16.41pp |
| 2020-12-31 | 6.63% | CN¥180.00 Million ≈ $26.34 Million |
CN¥2.72 Billion ≈ $397.47 Million |
-11.97pp |
| 2019-12-31 | 18.59% | CN¥355.78 Million ≈ $52.06 Million |
CN¥1.91 Billion ≈ $280.00 Million |
+2.88pp |
| 2018-12-31 | 15.72% | CN¥325.00 Million ≈ $47.56 Million |
CN¥2.07 Billion ≈ $302.60 Million |
-14.56pp |
| 2017-12-31 | 30.27% | CN¥500.00 Million ≈ $73.17 Million |
CN¥1.65 Billion ≈ $241.69 Million |
-6.93pp |
| 2016-12-31 | 37.20% | CN¥500.00 Million ≈ $73.17 Million |
CN¥1.34 Billion ≈ $196.67 Million |
-7.46pp |
| 2015-12-31 | 44.66% | CN¥600.00 Million ≈ $87.80 Million |
CN¥1.34 Billion ≈ $196.60 Million |
-- |
About Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Phar… Read more